Skip to main content
SpringerLink
Log in
Book cover

Serous Effusions pp 87–106Cite as

Malignant Mesothelioma

  • Chapter
  • First Online:

  • 539 Accesses

Abstract

Malignant mesothelioma is a rare malignant lung tumor with a very poor prognosis. A malignant effusion is frequently the first clinical symptom of the disease, and a definitive diagnosis can spare the patient further diagnostic procedures with the risk of spreading along the biopsy site. A large percentage of these effusions are highly cellular, particularly those with the epithelioid variant. Recently, the International Mesothelioma Interest Group (IMIG) acknowledged cytology as an acceptable diagnostic method, and supplemental guidelines for the diagnosis of mesothelioma by cytology were published. This chapter reviewed the epidemiology, the clinical presentation, and the morphologic features diagnostic of mesothelioma with its various patterns. The differential diagnoses and diagnostic pitfalls, particularly reactive mesothelial proliferations, are discussed in detail, along with the role of up-to-date immunohistochemistry in establishing a definitive diagnosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006;13(4):255–63.

    Article  PubMed  Google Scholar 

  2. Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. Aug 2009;133(8):1317–31.

    PubMed  Google Scholar 

  3. Hjerpe A, Ascoli V, Bedrossian CW, et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytol. 2015;59(1):2–16.

    Article  PubMed  CAS  Google Scholar 

  4. Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–67.

    Article  PubMed  Google Scholar 

  5. British Thoracic Society Standards of Care C. BTS statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(Suppl 2):ii1–ii19.

    Google Scholar 

  6. van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis. 2013;5(6):E254–307.

    PubMed  PubMed Central  Google Scholar 

  7. Bedrossian CW. Asbestos-related diseases: a historical and mineralogic perspective. Semin Diagn Pathol. 1992;9(2):91–6.

    PubMed  CAS  Google Scholar 

  8. Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases. Cancer. 1982;50(11):2423–32.

    Article  PubMed  CAS  Google Scholar 

  9. Mark EJ, Kradin RL. Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor. Semin Diagn Pathol. 2006;23(1):25–34.

    Article  PubMed  Google Scholar 

  10. Dogan AU, Dogan M, Hoskins JA. Erionite series minerals: mineralogical and carcinogenic properties. Environ Geochem Health. 2008;30(4):367–81.

    Article  PubMed  CAS  Google Scholar 

  11. Boylan AM. Mesothelioma: new concepts in diagnosis and management. Curr Opin Pulm Med. 2000;6(2):157–63.

    Article  PubMed  CAS  Google Scholar 

  12. Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. Oct 1997;9(4):347–55.

    PubMed  CAS  Google Scholar 

  13. Chirieac LR, Corson JM. Pathologic evaluation of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):121–4.

    Article  PubMed  Google Scholar 

  14. Alexander HR Jr. Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol. 2010;17(1):21–2.

    Article  PubMed  Google Scholar 

  15. Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer. 2002;94(2):378–85.

    Article  PubMed  Google Scholar 

  16. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447–53.

    Article  PubMed  CAS  Google Scholar 

  17. Antman KH, Osteen RT, Klegar KL, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2(8462):977–81.

    Article  PubMed  CAS  Google Scholar 

  18. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17(1):45–53.

    Article  PubMed  Google Scholar 

  19. Henderson DW. Malignant mesothelioma. New York: Hemisphere Publishing Corporation; 1992.

    Google Scholar 

  20. Matsuo T, Ito H, Anami M, Ikeda T, Nishihata S. Malignant peritoneal mesothelioma with squamous metaplasia. Cytopathology. 1993;4(6):373–8.

    Article  PubMed  CAS  Google Scholar 

  21. Mayall FG, Gibbs AR. The histology and immunohistochemistry of small cell mesothelioma. Histopathology. 1992;20(1):47–51.

    Article  PubMed  CAS  Google Scholar 

  22. Ordonez NG. Mesothelioma with clear cell features: an ultrastructural and immunohistochemical study of 20 cases. Hum Pathol. 2005;36(5):465–73.

    Article  PubMed  Google Scholar 

  23. Chang HT, Yantiss RK, Nielsen GP, McKee GT, Mark EJ. Lipid-rich diffuse malignant mesothelioma: a case report. Hum Pathol. 2000;31(7):876–9.

    Article  PubMed  CAS  Google Scholar 

  24. Klebe S, Mahar A, Henderson DW, Roggli VL. Malignant mesothelioma with heterologous elements: clinicopathological correlation of 27 cases and literature review. Modern Pathol. 2008;21(9):1084–94.

    Article  Google Scholar 

  25. Wilson GE, Hasleton PS, Chatterjee AK. Desmoplastic malignant mesothelioma: a review of 17 cases. J Clin Pathol. Apr 1992;45(4):295–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Ishikawa R, Kikuchi E, Jin M, et al. Desmoplastic malignant mesothelioma of the pleura: autopsy reveals asbestos exposure. Pathol Int. 2003;53(6):401–6.

    Article  PubMed  Google Scholar 

  27. Yao DX, Shia J, Erlandson RA, Klimstra DS. Lymphohistiocytoid mesothelioma: a clinical, immunohistochemical and ultrastructural study of four cases and literature review. Ultrastruct Pathol. 2004;28(4):213–28.

    Article  PubMed  Google Scholar 

  28. Henderson DW, Attwood HD, Constance TJ, Shilkin KB, Steele RH. Lymphohistiocytoid mesothelioma: a rare lymphomatoid variant of predominantly sarcomatoid mesothelioma. Ultrastruct Pathol. 1988;12(4):367–84.

    Article  PubMed  CAS  Google Scholar 

  29. Shia J, Erlandson RA, Klimstra DS. Deciduoid mesothelioma: a report of 5 cases and literature review. Ultrastruct Pathol. 2002;26(6):355–63.

    Article  PubMed  Google Scholar 

  30. Shanks JH, Harris M, Banerjee SS, et al. Mesotheliomas with deciduoid morphology: a morphologic spectrum and a variant not confined to young females. Am J Surg Pathol. 2000;24(2):285–94.

    Article  PubMed  CAS  Google Scholar 

  31. Ordonez NG. Epithelial mesothelioma with deciduoid features: report of four cases. Am J Surg Pathol. 2000;24(6):816–23.

    Article  PubMed  CAS  Google Scholar 

  32. Azzopardi JG. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol. 1959;78:513–9.

    Article  PubMed  CAS  Google Scholar 

  33. Talerman A, Montero JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13-year-old girl. Report of a case and review of the literature. Am J Surg Pathol. 1985;9(1):73–80.

    Article  PubMed  CAS  Google Scholar 

  34. Henley JD, Loehrer PJ Sr, Ulbright TM. Deciduoid mesothelioma of the pleura after radiation therapy for Hodgkin's disease presenting as a mediastinal mass. Am J Surg Pathol. 2001;25(4):547–8.

    Article  PubMed  CAS  Google Scholar 

  35. Serio G, Scattone A, Pennella A, et al. Malignant deciduoid mesothelioma of the pleura: report of two cases with long survival. Histopathology. 2002;40(4):348–52.

    Article  PubMed  CAS  Google Scholar 

  36. Paintal A. The evolving role of effusion cytology in the diagnosis of malignant mesothelioma. Cytopathology. 2015;26(3):137–8.

    Article  PubMed  CAS  Google Scholar 

  37. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest. 1997;111(1):106–9.

    Article  PubMed  CAS  Google Scholar 

  38. Nguyen GK. Cytopathology of pleural mesotheliomas. Am J Clin Pathol. 2000;114(Suppl):S68–81.

    PubMed  Google Scholar 

  39. Fetsch PA, Abati A. Immunocytochemistry in effusion cytology: a contemporary review. Cancer. 2001;93(5):293–308.

    Article  PubMed  CAS  Google Scholar 

  40. Westfall DE, Fan X, Marchevsky AM. Evidence-based guidelines to optimize the selection of antibody panels in cytopathology: pleural effusions with malignant epithelioid cells. Diagn Cytopathol. 2010;38(1):9–14.

    PubMed  Google Scholar 

  41. Rakha EA, Patil S, Abdulla K, Abdulkader M, Chaudry Z, Soomro IN. The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Diagn Cytopathol. 2010;38(12):874–9.

    Article  PubMed  CAS  Google Scholar 

  42. Tao LC. The cytopathology of mesothelioma. Acta Cytol. 1979;23(3):209–13.

    PubMed  CAS  Google Scholar 

  43. Hasegawa S, Kondo N, Matsumoto S, et al. Practical approaches to diagnose and treat for T0 malignant pleural mesothelioma: a proposal for diagnostic total parietal pleurectomy. Int J Clin Oncol. 2012;17(1):33–9.

    Article  PubMed  Google Scholar 

  44. Bedrossian CWM. The cytologic diagnosis of malignant mesothelioma. In: Michael CW, Bedrossian CWM, editors. Cytohistology of small tissue samples. Cambridge, UK Kingdom: Cambridge University Press; 2015.

    Google Scholar 

  45. Papanicolaou G. Atlas of exfoliative cytology. Cambridge, MA: harvard University Press; 1956.

    Google Scholar 

  46. Naylor B. The exfoliative cytology of diffuse malignant mesothelioma. J Pathol Bacteriol. 1963;86:293–8.

    Article  PubMed  CAS  Google Scholar 

  47. Roberts GH, Campbell GM. Exfoliative cytology of diffuse mesothelioma. J Clin Pathol. 1972;25(7):577–82.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Whitaker D, Shilkin KB. The cytology of malignant mesothelioma in Western Australia. Acta Cytol. 1978;22(2):67–70.

    PubMed  CAS  Google Scholar 

  49. Ehya H. The cytologic diagnosis of mesothelioma. Semin Diagn Pathol. 1986;3(3):196–203.

    PubMed  CAS  Google Scholar 

  50. Bedrossian CW, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunocytochemistry. Semin Diagn Pathol. 1992;9(2):124–40.

    PubMed  CAS  Google Scholar 

  51. Kho-Duffin J, Tao LC, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol. 1999;20(2):57–62.

    Article  PubMed  CAS  Google Scholar 

  52. Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol. 2007;128(3):414–22.

    Article  PubMed  Google Scholar 

  53. Whitaker D. Cell aggregates in malignant mesothelioma. Acta Cytol. 1977;21(2):236–9.

    PubMed  CAS  Google Scholar 

  54. Gillespie FR, van der Walt JD, Derias N, Kenney A. Deciduoid peritoneal mesothelioma. A report of the cytological appearances. Cytopathology. 2001;12(1):57–61.

    Article  PubMed  CAS  Google Scholar 

  55. Huang CC, Michael CW. Deciduoid mesothelioma: cytologic presentation and diagnostic pitfalls. Diagn Cytopathol. 2013;41(7):629–35.

    Article  PubMed  Google Scholar 

  56. Ustun H, Astarci HM, Sungu N, Ozdemir A, Ekinci C. Primary malignant deciduoid peritoneal mesothelioma: a report of the cytohistological and immunohistochemical appearances. Diagn Cytopathol. 2011;39(6):402–8.

    Article  PubMed  Google Scholar 

  57. Reis-Filho JS, Pope LZ, Milanezi F, Balderrama CM, Serapiao MJ, Schmitt FC. Primary epithelial malignant mesothelioma of the pericardium with deciduoid features: cytohistologic and immunohistochemical study. Diagn Cytopathol. 2002;26(2):117–22.

    Article  PubMed  Google Scholar 

  58. Ikeda K, Suzuki T, Tate G, Mitsuya T. Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: a case report. Diagn Cytopathol. 2008;36(7):512–5.

    Article  PubMed  Google Scholar 

  59. Hejmadi R, Ganesan R, Kamal NG. Malignant transformation of a well-differentiated peritoneal papillary mesothelioma. Acta Cytol. 2003;47(3):517–8.

    PubMed  Google Scholar 

  60. Cook DS, Attanoos RL, Jalloh SS, Gibbs AR. ‘Mucin-positive’ epithelial mesothelioma of the peritoneum: an unusual diagnostic pitfall. Histopathology. 2000;37(1):33–6.

    Article  PubMed  CAS  Google Scholar 

  61. Triol JH, Conston AS, Chandler SV. Malignant mesothelioma. Cytopathology of 75 cases seen in a New Jersey community hospital. Acta Cytol. 1984;28(1):37–45.

    PubMed  CAS  Google Scholar 

  62. Whitaker D, Shilkin KB. Diagnosis of pleural malignant mesothelioma in life—a practical approach. J Pathol. 1984;143(3):147–75.

    Article  PubMed  CAS  Google Scholar 

  63. Welker L, Muller M, Holz O, Vollmer E, Magnussen H, Jorres RA. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virch Arch. 2007;450(4):455–61.

    Article  CAS  Google Scholar 

  64. Ordonez NG. Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. Hum Pathol. 2013;44(1):1–19.

    Article  PubMed  CAS  Google Scholar 

  65. Beasley MB. Immunohistochemistry of pulmonary and pleural neoplasia. Arch Pathol Lab Med. 2008;132(7):1062–72.

    PubMed  CAS  Google Scholar 

  66. Ordonez NG. What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update. Hum Pathol. 2007;38(1):1–16.

    Article  PubMed  CAS  Google Scholar 

  67. Pu RT, Pang Y, Michael CW. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol. 2008;36(1):20–5.

    Article  PubMed  Google Scholar 

  68. Hanna A, Pang Y, Bedrossian CW, Dejmek A, Michael CW. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions. Diagn Cytopathol. 2010;38(4):264–9.

    PubMed  Google Scholar 

  69. Saad RS, Cho P, Liu YL, Silverman JF. The value of epithelial membrane antigen expression in separating benign mesothelial proliferation from malignant mesothelioma: a comparative study. Diagn Cytopathol. 2005;32(3):156–9.

    Article  PubMed  Google Scholar 

  70. Bassarova AV, Nesland JM, Davidson B. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Am J Surg Pathol. 2006;30(7):878–82.

    Article  PubMed  Google Scholar 

  71. Ascoli V, Scalzo CC, Taccogna S, Nardi F. The diagnostic value of thrombomodulin immunolocalization in serous effusions. Arch Pathol Lab Med. 1995;119(12):1136–40.

    PubMed  CAS  Google Scholar 

  72. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19-9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer. 1998;84(2):101–8.

    Article  PubMed  CAS  Google Scholar 

  73. Mimura T, Ito A, Sakuma T, et al. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma. Cancer. 2007;109(5):933–8.

    Article  PubMed  CAS  Google Scholar 

  74. Lozano MD, Panizo A, Toledo GR, Sola JJ, Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer. 2001;93(1):68–72.

    Article  PubMed  CAS  Google Scholar 

  75. Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122(4):299–306.

    Article  PubMed  Google Scholar 

  76. Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Mullerian carcinoma in effusions. Diagn Cytopathol. 2011;39(9):651–6.

    Article  PubMed  Google Scholar 

  77. Davidson B, Stavnes HT, Hellesylt E, et al. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. Hum Pathol. 2016;47(1):104–8.

    Article  PubMed  CAS  Google Scholar 

  78. Sack MJ, Roberts SA. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol. 1997;16(2):132–6.

    Article  PubMed  CAS  Google Scholar 

  79. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Modern Pathol. 2006;19(3):417–28.

    Article  Google Scholar 

  80. Hwang HC, Sheffield BS, Rodriguez S, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40(1):120–6.

    Article  PubMed  Google Scholar 

  81. Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Modern Pathol. 2015;28(8):1043–57.

    Article  CAS  Google Scholar 

  82. Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Modern Pathol. 2015;28(10):1360–8.

    Article  CAS  Google Scholar 

  83. Hasteh F, Lin GY, Weidner N, Michael CW. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions. Cancer Cytopathol. 2010;118(2):90–6.

    Article  PubMed  Google Scholar 

  84. Sivertsen S, Berner A, Michael CW, Bedrossian C, Davidson B. Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol. 2006;50(6):603–7.

    Article  PubMed  Google Scholar 

  85. Simsir A, Fetsch P, Mehta D, Zakowski M, Abati A. E-cadherin, N-cadherin, and calretinin in pleural effusions: the good, the bad, the worthless. Diagn Cytopathol. 1999;20(3):125–30.

    Article  PubMed  CAS  Google Scholar 

  86. Mutsaers SE. The mesothelial cell. Int J Biochem Cell Biology. 2004;36(1):9–16.

    Article  CAS  Google Scholar 

  87. Chen L, Caldero SG, Gmitro S, Smith ML, De Petris G, Zarka MA. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology. Cancer Cytopathol. 2014;122(1):70–5.

    Article  PubMed  CAS  Google Scholar 

  88. Gao L, Reeves W, Demay RM. Parakeratotic-like cells in effusions—a clue to diagnosis of malignant mesothelioma. Cytojournal. 2012;9:18.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Kimura N, Dota K, Araya Y, Ishidate T, Ishizaka M. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens. Diagn Cytopathol. 2009;37(12):885–90.

    Article  PubMed  Google Scholar 

  90. Cakir E, Demirag F, Aydin M, Unsal E. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: a logistic regression analysis. Diagn Cytopathol. 2009;37(1):4–10.

    Article  PubMed  Google Scholar 

  91. Ordonez NG. Value of immunohistochemistry in distinguishing peritoneal mesothelioma from serous carcinoma of the ovary and peritoneum: a review and update. Adv Anat Pathol. 2006;13(1):16–25.

    Article  PubMed  CAS  Google Scholar 

  92. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers. Virch Arch. 1999;435(1):43–9.

    Article  CAS  Google Scholar 

  93. Ordonez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005;36(11):1163–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, MSPTH 5077, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA

    Claire W. Michael

Authors
  1. Claire W. Michael
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claire W. Michael .

Editor information

Editors and Affiliations

  1. Department of Pathology, The Norwegian Radium Hospital Oslo University Hospital , Oslo, Norway

    Ben Davidson

  2. Department of Pathology, School of Medicine, Koç University, Istanbul, Turkey

    Pinar Firat

  3. UH Cleveland Medical Center, Case Western Reserve University, UH Clevel and Medical Center, Cleveland, Ohio, USA

    Claire W. Michael

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Michael, C.W. (2018). Malignant Mesothelioma. In: Davidson, B., Firat, P., Michael, C. (eds) Serous Effusions. Springer, Cham. https://doi.org/10.1007/978-3-319-76478-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76478-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76477-1

  • Online ISBN: 978-3-319-76478-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation